MedTrace Logo

Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

NCT04267016 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2021-09-28

No results posted yet for this study

Summary

This is an observational study in renal transplant recipients to evaluate the acceptability, feasibility, and clinical utility of TruGraf® testing in conjunction with standard clinical assessment. TruGraf is the first and only non-invasive test approved by Medicare to rule out silent rejection in stable kidney transplant recipients.

Conditions

  • Kidney Transplant Rejection

Interventions

DIAGNOSTIC_TEST

TruGraf Testing - Peripheral blood gene expression profiling

5 mL collection PAXgene blood sample

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Transplant Genomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patty West-Thielke, PharmD · Transplant Genomics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2021-05-11
Completion
2021-05-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04267016 on ClinicalTrials.gov